Fiche publication
Date publication
septembre 2015
Journal
La Revue de medecine interne
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FOHRER Cécile
Tous les auteurs :
Fouquet G, Macro M, Decaux O, Fohrer C, Guidez S, Demarquette H, Le Grand C, Prodhomme C, Renaud L, Bories C, Herbaux C, Karlin L, Roussel M, Benboubker L, Hulin C, Arnulf B, Leleu X
Lien Pubmed
Résumé
Once characterized by a very poor outcome, multiple myeloma (MM) now has a significantly prolonged survival, with major improvements allowed by the use of "novel agents": proteasome inhibitors (first-in-class bortezomib) and immunomodulatory compounds (IMiDs; first-in-class thalidomide and lenalidomide). However, the vast majority - if not all - of patients with MM ultimately end up being refractory to all existing drugs, including these efficient novel agents. There is a clear unmet medical need in this situation, which warrants the development of the next generation of proteasome inhibitors and IMiDs, as well as new drug classes. This review focuses on pomalidomide, the next generation IMiD, recently approved by the US FDA and the EMA for patients with relapsed or refractory MM who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on their last therapy.
Mots clés
Antineoplastic Agents, chemistry, Clinical Trials as Topic, methods, Humans, Molecular Conformation, Multiple Myeloma, drug therapy, Structure-Activity Relationship, Thalidomide, analogs & derivatives
Référence
Rev Med Interne. 2015 Sep;36(9):613-8
